Positive data sends Amplia Therapeutics nearly 50 per cent up

Biotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data.

The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK).

To view media story please click here.